A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma
Keyword(s):
Us Fda
◽
Although surgical therapy continues to be the gold standard for the treatment of basal cell carcinoma given high cure rates and the ability to histologically confirm tumor clearance, there are a number of nonsurgical treatment options that may be considered based on individual tumor characteristics, functional and cosmetic considerations, patient comorbidities and patient preference. Topical 5-fluorouracil 5% cream and imiquimod 5% cream have been US FDA-approved for the treatment of superficial basal cell carcinoma. Additionally, a number of new and emerging topical agents and techniques have been described for the treatment of basal cell carcinoma and will be reviewed herein.
Keyword(s):
2018 ◽
Vol 22
(4)
◽
pp. 400-404
Keyword(s):
2008 ◽
Vol 19
(3)
◽
pp. 156-158
◽
2014 ◽
Vol 172
(3)
◽
pp. 739-745
◽